FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] The company is in the healthcare service segment where there is rising competition and is a fragmented sector. While it posted growth in its top lines for the last three fiscals, its bottom line posted inconsistency. Its comparison with listed peers is an eyewash. Based on FY23 earnings, the issue appears aggressively priced. Investors may skip this pricey IPO. Read detail review...
Sangani Hospitals Limited peer comparison with similar listed entities. () (As on March 31, 2022)
Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | |
---|---|---|---|---|---|
EPS Basic | EPS Diluted | ||||
Sangani Hospitals Limited | 5.56 | 5.56 | 12.70 | 65.46 | |
Artemis Medicare Services Limited | 2.40 | 2.29 | 21.17 | 33.49 | 7.17 |
Lotus Eye Hospital And Institute Ltd | 1.44 | 1.44 | 24.65 | 48.47 | 5.48 |
Sangani Hospitals IPO Reviews, analysis and views by popular members. Read Sangani Hospitals Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 100.00 | 0.00 |
Member | Review |
---|---|
B.M.SURANA IPO Guru (2700+ Posts, 5300+ Likes) |
Neutral Bahut Mehnga lagta hai. August 6, 2023 1:02:52 PM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|